Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 4/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | BTK | Q06187 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29291567 | 0.83 | CIT (0.57) | CITROCK2CYP3A4CYP3A5LIMK1 | |
| SCHEMBL30009111 | 0.81 | ROCK2 (0.60) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL28871098 | 0.81 | CIT (0.63) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL30009593 | 0.81 | RAB9A (0.51) | CITROCK2CYP3A4CYP3A5LIMK1 | |
| SCHEMBL30009442 | 0.80 | CIT (0.62) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL20917947 | 0.78 | JAK1 (0.78) | JAK1 | |
| SCHEMBL30009600 | 0.78 | LIMK1 (0.61) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL24121895 | 0.77 | CIT (0.53) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL28345572 | 0.77 | JAK3 (0.74) | KITCITROCK2CYP3A4CYP3A5 | |
| SCHEMBL30009617 | 0.76 | JAK1 (0.63) | KITCITROCK2CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KIT 3668/4885CIT 417/4885ROCK2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.